Heart HealthResearch PaperOpen Access

Clonal blood mutations did not raise artery plaque or inflammation in people with treated HIV

In 230 people with treated HIV, clonal hematopoiesis (CHIP) did not track with carotid thickening or aortic inflammation, but lymph node activity rose.

Friday, November 20, 2026 2 views
Published in medRxiv
carotid artery ultrasound scan of a man's neck by a technician in a dim clinic room

Summary

Clonal hematopoiesis (CHIP) is an age-related expansion of blood stem cells carrying mutations. It raises heart disease risk in the general population and is twice as common in people with HIV. Researchers tested whether CHIP drives artery disease in 230 adults with treated, suppressed HIV. About 14% had CHIP. Overall, CHIP was not linked to carotid wall thickness, plaque, aortic inflammation on PET scans, or blood inflammation markers. The one signal was higher metabolic activity in lymph nodes, which weakened after adjustment, so it is only a hint. A post-hoc look at the most common mutation type, DNMT3A, suggested slightly faster carotid thickening. The study was small and observational, so it cannot rule out an effect, and it does not show CHIP is harmless in HIV.

Detailed Summary

Clonal hematopoiesis of indeterminate potential (CHIP) is a age-linked state in which blood stem cells carry acquired mutations (variant allele fraction above 2%) and expand. In the general population it is tied to heart attack risk, and mouse work points to inflammasome and IL-6 and IL-1β signaling as a causal route. HIV roughly doubles both CHIP prevalence and cardiovascular risk, so this paper asked whether CHIP is a mechanism behind HIV-related atherosclerosis.

The team studied 230 people with HIV on effective treatment (age 52±9, 7% women, viral load under 40 copies/ml) from the SCOPE cohort and related imaging protocols. CHIP was found with targeted sequencing of 22 genes by a blinded core lab. Carotid intima-media thickness (IMT) was measured by ultrasound at baseline and a median 3.5 years later in 166 people. Aortic inflammation and lymph node activity were assessed once with 18F-FDG-PET in 80 people. Blood inflammatory markers and HIV reservoir measures were also analyzed.

Thirty-two participants (14%) had CHIP, mostly DNMT3A (n=21) and TET2 (n=6), with a median clone size of 2.8%. Each decade of age doubled the odds of CHIP (OR 2.0, 95% CI 1.3-3.01). Predicted 10-year cardiovascular risk was higher with CHIP (8.7% vs 5.1%, p=0.044). Baseline IMT was not different (1.093 vs 1.001 mm, p=0.21; adjusted p=0.76-0.77), nor was IMT progression over 3.5 years (p=0.78) or plaque (65% vs 54%, OR 1.61, 95% CI 0.64-4.02). Aortic target-to-background ratio was essentially identical (3.02 vs 3.06, p=0.89).

Inflammatory markers, including IL-6, TNF, sCD14, sCD163, MCP1, D-dimer and fibrinogen, did not differ by CHIP status. Nor did the intact proviral reservoir (p=0.72); cell-associated HIV DNA trended higher (p=0.08). The unplanned signal was higher lymph node SUVmax with CHIP (1.37 vs 1.20, p=0.017, n=50, 9 with CHIP), but it lost significance after adjustment for age, sex and risk factors and when referenced to blood pool activity. Authors frame it as hypothesis-generating, possibly reflecting CHIP-mutated or HIV-infected cells harbored in nodes.

Post-hoc subtype analyses went in a notable direction. DNMT3A CHIP showed greater IMT and faster progression in unadjusted models, but the baseline difference vanished after adjusting for age and sex, and these were not prespecified. Non-DNMT3A CHIP showed slightly slower progression. This contrasts with UK Biobank data, where non-DNMT3A CHIP carries the coronary risk. The mechanism linking CHIP to atherosclerosis therefore remains unproven in treated HIV; these are human surrogate-endpoint data, not clinical events.

Caveats are substantial. Only 12 people with CHIP had PET and 23 had IMT, so power was low and moderate effects could be missed. TET2 carriers, with the strongest causal evidence, numbered six. Follow-up was short, CHIP carriers were older, women were scarce, and imaging was not available for everyone. Chronic HIV inflammation may also mask CHIP's added effect. Larger studies with clinical events are needed.

Key Findings

  • 14% (32/230) of people with treated HIV had CHIP, median clone size 2.8%; DNMT3A (n=21) and TET2 (n=6) were most common
  • Older age doubled CHIP odds per decade (OR 2.0, 95% CI 1.3-3.01, p=0.002)
  • Mechanism/structure null: baseline carotid IMT 1.093 vs 1.001 mm (p=0.21), adjusted p=0.76-0.77; no faster progression over 3.5 years (p=0.78)
  • Aortic FDG-PET inflammation did not differ (TBR 3.02 vs 3.06, p=0.89, n=80, 12 with CHIP)
  • No CHIP association with IL-6, TNF, sCD14, sCD163, MCP1, D-dimer or fibrinogen, or with intact proviral reservoir (p=0.72)
  • Lymph node SUVmax higher with CHIP (1.37 vs 1.20, p=0.017, n=50), but lost significance after adjustment or blood-pool referencing
  • Post-hoc, unadjusted DNMT3A CHIP showed faster IMT progression (p=0.003); baseline difference disappeared after age/sex adjustment

Methodology

Observational cohort of 230 adults with treated, suppressed HIV in the SCOPE cohort, with CHIP detected by blinded targeted sequencing (22 genes, VAF >2%). Carotid IMT was measured at baseline and about 3.5 years (n=166), and FDG-PET was cross-sectional (n=80). Analyses used Wilcoxon, Fisher's exact, linear regression, mixed-effects models for IMT and logistic regression for plaque, adjusted for age, sex and cardiovascular and HIV factors. Secondary and subtype analyses were exploratory with no multiple-testing correction.

Study Limitations

Few participants with CHIP had imaging (23 for IMT, 12 for PET), limiting power, especially for TET2 and mutation-specific effects. CHIP carriers were older, only 7% were women, follow-up was short, and measurements came from other protocols so not everyone had every test. Subtype and lymph node findings were post-hoc or unplanned, and no conflicts of interest were stated in the supplied text.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: